MannKind (MNKD) is back in focus after presenting a broad package of Afrezza and FUROSCIX data at the American Diabetes ...

MannKind Corporation (NASDAQ:MNKD) is among the hidden penny stocks to invest in. On June 1, Wells Fargo lifted the price ...

MannKind (NASDAQ:MNKD) said the U.S. Food and Drug Administration has approved Afrezza for pediatric patients with diabetes ages 6 and older, expanding the inhaled mealtime insulin's label into ...

MannKind posted Phase 3 trial results last October, comparing Afrezza in patients aged 4 to 17, with multiple daily insulin injections. ・MannKind will present additional Afrezza-related data at the ...

MannKind recently received U.S. FDA approval for Afrezza Inhalation Powder for children and adolescents aged 6 and older with type 1 or type 2 diabetes, making it the first needle-free mealtime ...

MannKind Corporation announced today that it plans to meet with the FDA to discuss a potential supplemental new drug application (sNDA) for its inhaled insulin product, Afrezza, following positive six ...

With MannKind having finally gained Food and Drug Administration approval for its inhaled insulin Afrezza, you'd think the hard part was behind the company. It's not. Now that it's approved, MannKind ...

MannKind (NASDAQ:MNKD) develops and manufactures inhalable therapies, mainly targeting diabetes and rare lung diseases. Its flagship product is Afrezza, an inhaled insulin powder designed to offer ...

MannKind Corporation is transitioning from a volatile biotech to a diversified, revenue-driven pharma, with FUROSCIX and Afrezza driving commercial momentum. MNKD’s 2026 business outlook highlights ...

View MannKind Corporation MNKD stock quote prices, financial information, real-time forecasts, and company news from CNN.

Discover high-conviction stock picks and new investing opportunities with the TipRanks Smart Investor Newsletter An update from MannKind ( (MNKD)) is now available. On May 27, 2026, MannKind received ...

Revenue (GAAP) rose 6% to $76.5 million in the second quarter of 2025 but missed the revenue (GAAP) estimate by $2.26 million. Non-GAAP EPS held steady at $0.05, matching both estimates and last ...